Key Highlights

  • Bluejay Diagnostics (NASDAQ:BJDX) indicated USD 2.26 pre-market on November 10, 2026, down 9.24% from a calculated prior close of USD 2.49, a fall of about USD 0.23 per share.
  • A 1-for-4 reverse split took effect on November 3, 2026, cutting shares outstanding from about 4.5 million to about 1.1 million under the unchanged BJDX symbol.
  • Simple arithmetic on 1.1 million shares at USD 2.26 gives a calculated Market Value near USD 2.5 million, a nano-cap scale where small orders move the price.
  • On a pre-split basis the USD 2.26 quote equals about USD 0.565 per old share, calculated by dividing by 4, and the prior close equals about USD 0.62.

What Moved Bluejay Diagnostics Pre-Market (down 9.24%)

No company release or filing dated November 9 or November 10, 2026 was identified in published coverage, so no same-day catalyst is confirmed. The latest confirmed event is the 1-for-4 reverse split approved by the board and effective November 3, 2026, which combined every four common shares into one. Outstanding shares fell from about 4.5 million to about 1.1 million, and the new CUSIP is 095633707. Fractional shares are paid in cash, and the stock still trades on The Nasdaq Capital Market. Published coverage also showed quarterly results expected on Friday, November 6, 2026, but no figures were retrieved. At USD 2.26 the quote sits USD 1.26 above the USD 1.00 Nasdaq minimum bid level, calculated. The indicated price of USD 2.26 compares with a calculated Monday close of USD 2.49.

The Rationale: Reverse Splits and Nano-Cap Dynamics

The release gave no reason for the split and no Nasdaq deficiency details, so the motive is not confirmed. As general context, companies often use reverse splits to lift the share price above the USD 1.00 minimum bid that Nasdaq requires, yet the split does not change the market value of a holding by itself. It only divides the share count by 4 and multiplies the price by 4. Stocks can drift lower after a split when holders who bought the old shares sell, when new financing is expected, or when the price simply reverts. A pre-market drop of 9.24% from USD 2.49 to USD 2.26 fits that pattern, but no cause is confirmed here.

Valuation, Liquidity and Risks Around Bluejay Diagnostics

With roughly 1.1 million shares outstanding, the public float is very small, so a few hundred trades can move the indicated price by several cents. Spreads in pre-market sessions can be wide, and the 9.24% move may reverse by the open. Diagnostics developers with limited Revenue typically fund operations through Equity offerings, and any new issuance would dilute a base this small. Average volume, cash, Debt and the 52-week range were not verified in the research window, so none is quoted. A 9.24% move on a base of 1.1 million shares can involve only a few thousand shares changing hands. The post-split price history also is not comparable with quotes before November 3, 2026 unless adjusted by the Factor of 4.

Where Things Stand

Bluejay Diagnostics (NASDAQ:BJDX) is down 9.24% pre-market at USD 2.26, with no catalyst identified in published coverage dated November 9 or 10, 2026. The most recent confirmed event is the 1-for-4 reverse split effective November 3, 2026, which cut shares outstanding to about 1.1 million. A market value near USD 2.5 million, calculated, leaves the stock exposed to thin trade, dilution and reversal.